Literature DB >> 1357507

Who should receive a 5-HT3 antagonist?

S B Kaye, D Khayat, M Aapro, V Diehl.   

Abstract

Mesh：

Substances：

Year:  1992        PMID： 1357507     DOI： 10.1016/0140-6736(92)93138-d

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

1.  Once more: prevention of nausea and emesis in cancer treatment.

Authors:  M S Aapro
Journal:  Support Care Cancer       Date:  1994-05       Impact factor: 3.603

Review 2.  Costs and benefits of antiemetic therapy.

Authors:  M S Aapro
Journal:  Support Care Cancer       Date:  1994-09       Impact factor: 3.603

3.  Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin.

Authors:  K Matsui; M Fukuoka; M Takada; Y Kusunoki; T Yana; K Tamura; T Yoshida; K Iida; T Hirashima; H Tsukada; S Ushijima; H Miyawaki; N Masuda
Journal:  Br J Cancer       Date:  1996-01       Impact factor: 7.640
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.